首页> 外文期刊>Biochimica et biophysica acta. Biomembranes >Allosteric modulation of adenosine receptors.
【24h】

Allosteric modulation of adenosine receptors.

机译:腺苷受体的变构调节。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Allosteric ligands for G protein-coupled receptors (GPCRs) may alter receptor conformations induced by an orthosteric ligand. These modulators can thus fine-tune classical pharmacological responses. In this review we will describe efforts to synthesize and characterize allosteric modulators for one particular GPCR subfamily, the adenosine receptors. There are four subtypes of these receptors: A(1), A(2A), A(2B) and A(3). Allosteric enhancers for the adenosine A(1) receptor may have anti-arrythmic and anti-lipolytic activity. They may also act as analgesics and neuroprotective agents. A(3) allosteric enhancers are thought to be beneficial in ischemic conditions or as antitumor agents. We will summarize recent developments regarding the medicinal chemistry of such compounds. Most data have been and are published about the adenosine A(1) and A(3) receptor, whereas limited or no information is available for the A(2A) and A(2B) receptor, respectively. Receptor mutation studies are also discussed, as they may shed light on the localization of the allosteric binding sites. This article is part of a Special Issue entitled: "Adenosine Receptors".
机译:G蛋白偶联受体(GPCR)的变构配体可能会改变正构配体诱导的受体构象。这些调节剂因此可以微调经典药理反应。在这篇综述中,我们将描述为一个特定的GPCR亚家族,腺苷受体,合成和表征变构调节剂的努力。这些受体有四种亚型:A(1),A(2A),A(2B)和A(3)。腺苷A(1)受体的变构增强剂可能具有抗心律失常和抗脂解的活性。它们还可以作为止痛药和神经保护剂。 A(3)变构增强剂被认为在缺血条件下或作为抗肿瘤药物是有益的。我们将总结关于此类化合物的药物化学的最新进展。关于腺苷A(1)和A(3)受体的大多数数据已经被发表,而有关A(2A)和A(2B)受体的信息有限或没有可用的信息。还讨论了受体突变研究,因为它们可能揭示了变构结合位点的定位。本文是名为“腺苷受体”的特刊的一部分。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号